Myriad Genetics Inc
NASDAQ:MYGN
Myriad Genetics Inc
Revenue
Myriad Genetics Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Myriad Genetics Inc
NASDAQ:MYGN
|
Revenue
$753.2m
|
CAGR 3-Years
36%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Myriad Genetics Inc
Revenue Breakdown
Breakdown by Geography
Myriad Genetics Inc
Total Revenue:
753.2m
USD
|
United States:
671.7m
USD
|
Rest Of World:
81.5m
USD
|
Breakdown by Segments
Myriad Genetics Inc
Total Revenue:
753.2m
USD
|
Testing Revenue:
753.2m
USD
|
See Also
What is Myriad Genetics Inc's Revenue?
Revenue
753.2m
USD
Based on the financial report for Dec 31, 2023, Myriad Genetics Inc's Revenue amounts to 753.2m USD.
What is Myriad Genetics Inc's Revenue growth rate?
Revenue CAGR 10Y
0%
Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for Myriad Genetics Inc have been 36% over the past three years , -1% over the past five years .